Logo image of IMUX

IMMUNIC INC (IMUX) Stock Price, Quote, News and Overview

NASDAQ:IMUX - Nasdaq - US4525EP1011 - Common Stock - Currency: USD

0.6599  -0.02 (-2.96%)

After market: 0.67 +0.01 (+1.53%)

IMUX Quote, Performance and Key Statistics

IMMUNIC INC

NASDAQ:IMUX (5/30/2025, 8:05:04 PM)

After market: 0.67 +0.01 (+1.53%)

0.6599

-0.02 (-2.96%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.11
52 Week Low0.56
Market Cap63.23M
Shares95.82M
Float94.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/bmo
IPO04-17 2014-04-17


IMUX short term performance overview.The bars show the price performance of IMUX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

IMUX long term performance overview.The bars show the price performance of IMUX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IMUX is 0.6599 USD. In the past month the price decreased by -43.6%. In the past year, price decreased by -46.78%.

IMMUNIC INC / IMUX Daily stock chart

IMUX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.74B
AMGN AMGEN INC 13.88 154.96B
GILD GILEAD SCIENCES INC 14.22 136.93B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.52B
REGN REGENERON PHARMACEUTICALS 11.06 52.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.71B
ARGX ARGENX SE - ADR 97.66 35.00B
ONC BEONE MEDICINES LTD-ADR 6.28 26.55B
BNTX BIONTECH SE-ADR N/A 23.03B
NTRA NATERA INC N/A 21.54B
BIIB BIOGEN INC 8.2 19.02B
UTHR UNITED THERAPEUTICS CORP 12.72 14.38B

About IMUX

Company Profile

IMUX logo image Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Company Info

IMMUNIC INC

1200 Avenue Of The Americas, Suite 200

New York City NEW YORK 10036 US

CEO: Daniel Vitt

Employees: 91

IMUX Company Website

IMUX Investor Relations

Phone: 13322559818

IMMUNIC INC / IMUX FAQ

What is the stock price of IMMUNIC INC today?

The current stock price of IMUX is 0.6599 USD. The price decreased by -2.96% in the last trading session.


What is the ticker symbol for IMMUNIC INC stock?

The exchange symbol of IMMUNIC INC is IMUX and it is listed on the Nasdaq exchange.


On which exchange is IMUX stock listed?

IMUX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IMMUNIC INC stock?

13 analysts have analysed IMUX and the average price target is 15.13 USD. This implies a price increase of 2192.77% is expected in the next year compared to the current price of 0.6599. Check the IMMUNIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IMMUNIC INC worth?

IMMUNIC INC (IMUX) has a market capitalization of 63.23M USD. This makes IMUX a Micro Cap stock.


How many employees does IMMUNIC INC have?

IMMUNIC INC (IMUX) currently has 91 employees.


What are the support and resistance levels for IMMUNIC INC (IMUX) stock?

IMMUNIC INC (IMUX) has a resistance level at 1.18. Check the full technical report for a detailed analysis of IMUX support and resistance levels.


Should I buy IMMUNIC INC (IMUX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IMMUNIC INC (IMUX) stock pay dividends?

IMUX does not pay a dividend.


When does IMMUNIC INC (IMUX) report earnings?

IMMUNIC INC (IMUX) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of IMMUNIC INC (IMUX)?

IMMUNIC INC (IMUX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).


What is the Short Interest ratio of IMMUNIC INC (IMUX) stock?

The outstanding short interest for IMMUNIC INC (IMUX) is 2.89% of its float. Check the ownership tab for more information on the IMUX short interest.


IMUX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IMUX Financial Highlights

Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 48.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -469.88%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%16.67%
Sales Q2Q%N/A
EPS 1Y (TTM)48.09%
Revenue 1Y (TTM)N/A

IMUX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to IMUX. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners59.43%
Ins Owners1.01%
Short Float %2.89%
Short Ratio3
Analysts
Analysts84.62
Price Target15.13 (2192.77%)
EPS Next Y23.5%
Revenue Next YearN/A